KR102860817B1 - 트라디피턴트에 의한 치료 방법 - Google Patents

트라디피턴트에 의한 치료 방법

Info

Publication number
KR102860817B1
KR102860817B1 KR1020237043041A KR20237043041A KR102860817B1 KR 102860817 B1 KR102860817 B1 KR 102860817B1 KR 1020237043041 A KR1020237043041 A KR 1020237043041A KR 20237043041 A KR20237043041 A KR 20237043041A KR 102860817 B1 KR102860817 B1 KR 102860817B1
Authority
KR
South Korea
Prior art keywords
tradipitant
pharmaceutical composition
pruritus
treatment
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020237043041A
Other languages
English (en)
Korean (ko)
Other versions
KR20230173743A (ko
Inventor
미하엘 에이치. 폴리머로폴로스
루이스 윌리엄 리카멜
Original Assignee
반다 파마슈티칼즈, 인코퍼레이티드.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 반다 파마슈티칼즈, 인코퍼레이티드. filed Critical 반다 파마슈티칼즈, 인코퍼레이티드.
Priority to KR1020257030197A priority Critical patent/KR20250136946A/ko
Publication of KR20230173743A publication Critical patent/KR20230173743A/ko
Application granted granted Critical
Publication of KR102860817B1 publication Critical patent/KR102860817B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Encapsulation Of And Coatings For Semiconductor Or Solid State Devices (AREA)
  • Medicinal Preparation (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Eye Examination Apparatus (AREA)
KR1020237043041A 2015-03-04 2016-03-04 트라디피턴트에 의한 치료 방법 Active KR102860817B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257030197A KR20250136946A (ko) 2015-03-04 2016-03-04 트라디피턴트에 의한 치료 방법

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562128472P 2015-03-04 2015-03-04
US62/128,472 2015-03-04
US201562232644P 2015-09-25 2015-09-25
US62/232,644 2015-09-25
PCT/US2016/021015 WO2016141341A1 (en) 2015-03-04 2016-03-04 Method of treatment with tradipitant
KR1020177026588A KR20170122777A (ko) 2015-03-04 2016-03-04 트라디피턴트에 의한 치료 방법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020177026588A Division KR20170122777A (ko) 2015-03-04 2016-03-04 트라디피턴트에 의한 치료 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257030197A Division KR20250136946A (ko) 2015-03-04 2016-03-04 트라디피턴트에 의한 치료 방법

Publications (2)

Publication Number Publication Date
KR20230173743A KR20230173743A (ko) 2023-12-27
KR102860817B1 true KR102860817B1 (ko) 2025-09-16

Family

ID=55629110

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020237043041A Active KR102860817B1 (ko) 2015-03-04 2016-03-04 트라디피턴트에 의한 치료 방법
KR1020257030197A Pending KR20250136946A (ko) 2015-03-04 2016-03-04 트라디피턴트에 의한 치료 방법
KR1020177026588A Ceased KR20170122777A (ko) 2015-03-04 2016-03-04 트라디피턴트에 의한 치료 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020257030197A Pending KR20250136946A (ko) 2015-03-04 2016-03-04 트라디피턴트에 의한 치료 방법
KR1020177026588A Ceased KR20170122777A (ko) 2015-03-04 2016-03-04 트라디피턴트에 의한 치료 방법

Country Status (19)

Country Link
US (6) US10463655B2 (enExample)
EP (2) EP3730140A1 (enExample)
JP (4) JP6891385B2 (enExample)
KR (3) KR102860817B1 (enExample)
CN (2) CN113262221A (enExample)
AU (4) AU2016226006B2 (enExample)
BR (1) BR112017018620A2 (enExample)
CA (2) CA2978736C (enExample)
CL (1) CL2017002238A1 (enExample)
DK (1) DK3265087T3 (enExample)
ES (1) ES2824552T3 (enExample)
HR (1) HRP20201627T1 (enExample)
HU (1) HUE050944T2 (enExample)
IL (1) IL254142B (enExample)
MX (2) MX385788B (enExample)
PT (1) PT3265087T (enExample)
RU (1) RU2770050C2 (enExample)
WO (1) WO2016141341A1 (enExample)
ZA (1) ZA201706059B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016141341A1 (en) * 2015-03-04 2016-09-09 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
CA3073998A1 (en) * 2017-09-13 2019-03-21 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
HRP20250615T1 (hr) 2017-11-17 2025-07-18 Vanda Pharmaceuticals Inc. Tradipitant za upotrebu u liječenju gastropareze
US20210228555A1 (en) * 2018-06-08 2021-07-29 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
CN111918701B (zh) * 2018-09-28 2024-08-02 万达制药公司 曲地匹坦在晕动病中的用途
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
WO2020117811A1 (en) 2018-12-03 2020-06-11 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
WO2020132513A1 (en) 2018-12-21 2020-06-25 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
WO2021173641A1 (en) 2020-02-25 2021-09-02 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
JP7791832B2 (ja) * 2020-03-26 2025-12-24 バンダ・ファーマシューティカルズ・インコーポレイテッド トラジピタントによる下気道感染症の治療
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
JP2025542424A (ja) 2022-12-21 2025-12-25 バンダ・ファーマシューティカルズ・インコーポレイテッド トラジピタントによる処置の方法
EP4599831A1 (en) 2024-02-09 2025-08-13 Vanda Pharmaceuticals Inc. Treatment of gastroparesis with tradipitant

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9305718D0 (en) * 1993-03-19 1993-05-05 Glaxo Group Ltd Medicaments
TW263498B (enExample) * 1993-11-10 1995-11-21 Takeda Pharm Industry Co Ltd
GB9513972D0 (en) 1995-07-08 1995-09-06 Merck Sharp & Dohme Pharmaceutical compositions
DE60045564D1 (de) 1999-02-24 2011-03-03 Hoffmann La Roche 4-Phenylpyridinderivate und deren Verwendung als NK-1 Rezeptorantagonisten
US6849624B2 (en) * 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
WO2003091227A1 (en) * 2002-04-26 2003-11-06 Eli Lilly And Company Tachykinin receptor antagonists
AU2003230829B8 (en) 2002-04-26 2008-12-11 Eli Lilly And Company Triazole derivatives as tachykinin receptor antagonists
JP2004250329A (ja) 2002-12-26 2004-09-09 Dainippon Pharmaceut Co Ltd イサチン誘導体
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
KR100848407B1 (ko) 2003-10-24 2008-07-28 일라이 릴리 앤드 캄파니 ｛2-[1-(3,5-비스-트리플루오로메틸벤질)-5-피리딘-4-일-1ｈ-[1,2,3]트리아졸-4-일]-피리딘-3-일｝-(2-클로로페닐)-메탄온의 신규 결정질 형태
JP4673068B2 (ja) 2005-01-19 2011-04-20 独立行政法人科学技術振興機構 Ｔｈ１型アレルギー疾患治療用組成物
DE102005006217B4 (de) 2005-02-07 2007-08-16 Universitätsklinikum Hamburg-Eppendorf Diagnose von allergischen Erkrankungen und/oder atopischen Erkrankungen durch Nachweis von Autoantikörpern gegen CD28 in humanem Serum
US20090264388A1 (en) 2006-02-22 2009-10-22 Valorisation Recherche Hscm, Limited Partnership Compounds and Methods of Treating Disorders Associated With Activation of Metachromatic Cells
WO2008079600A1 (en) 2006-12-20 2008-07-03 Eli Lilly And Company Novel intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
CN102573475B (zh) 2009-08-14 2016-01-20 欧科生医股份有限公司 神经激肽-1拮抗剂的静脉内制剂
HRP20140759T1 (hr) 2009-11-18 2014-10-24 Helsinn Healthcare S.A. Kompozicije za lijeäśenje središnje posredovane muäśnine i povraä†anja
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
WO2014093907A1 (en) 2012-12-13 2014-06-19 A.P. Pharma, Inc. Pharmaceutical composition comprising antiemetic compounds and polyorthoester
JP6644328B2 (ja) 2013-02-28 2020-02-12 ロート製薬株式会社 アトピー性疾患の発症又は重症化リスクの評価法
US8906951B1 (en) * 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
HK1223820A1 (zh) * 2013-06-24 2017-08-11 Menlo Therapeutics Inc. Nk-1受体拮抗剂司洛匹坦在瘙痒中的用途
WO2016141341A1 (en) * 2015-03-04 2016-09-09 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
WO2016195723A1 (en) 2015-06-03 2016-12-08 Beller Pharmaceuticals LLC Methods of treatment for conditions mediated by substance p
WO2017060488A1 (en) 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists
MX378145B (es) 2015-11-30 2025-03-10 Anacor Pharmaceuticals Inc Formulaciones farmacéuticas tópicas que comprenden crisaborol para tratar afecciones inflamatorias
CA3009325A1 (en) 2015-12-22 2017-06-29 Takeda Pharmaceutical Company Limited Tripartite modulators of endosomal g protein-coupled receptors
CA3073998A1 (en) * 2017-09-13 2019-03-21 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
HRP20250615T1 (hr) * 2017-11-17 2025-07-18 Vanda Pharmaceuticals Inc. Tradipitant za upotrebu u liječenju gastropareze
US20210228555A1 (en) * 2018-06-08 2021-07-29 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
CN111918701B (zh) * 2018-09-28 2024-08-02 万达制药公司 曲地匹坦在晕动病中的用途
WO2020117811A1 (en) * 2018-12-03 2020-06-11 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
European Neuropsychopharmacology, 2010, 20(2), 80-87
PloS one, 2010, 5(6), e10968*
Science, 2008, 319(5869), 1536-1539*

Also Published As

Publication number Publication date
EP3730140A1 (en) 2020-10-28
MX385788B (es) 2025-03-18
HRP20201627T1 (hr) 2021-02-19
US10772880B2 (en) 2020-09-15
CL2017002238A1 (es) 2018-04-20
CN113262221A (zh) 2021-08-17
AU2023233141A1 (en) 2023-10-12
WO2016141341A1 (en) 2016-09-09
US20200360358A1 (en) 2020-11-19
US10463655B2 (en) 2019-11-05
CA3213864C (en) 2026-02-03
US11324735B2 (en) 2022-05-10
AU2016226006B2 (en) 2021-03-04
EP3265087B1 (en) 2020-07-22
CA2978736A1 (en) 2016-09-09
KR20230173743A (ko) 2023-12-27
MX2017011279A (es) 2018-01-25
US20220226295A1 (en) 2022-07-21
MX2021010460A (es) 2021-09-21
BR112017018620A2 (pt) 2018-04-17
RU2017134443A (ru) 2019-04-04
CA2978736C (en) 2023-11-07
AU2023233141B2 (en) 2025-05-22
DK3265087T3 (da) 2020-10-19
HUE050944T2 (hu) 2021-01-28
US20180110761A1 (en) 2018-04-26
ZA201706059B (en) 2023-08-30
IL254142B (en) 2022-05-01
AU2016226006A1 (en) 2017-09-21
EP3265087A1 (en) 2018-01-10
RU2770050C2 (ru) 2022-04-14
NZ735121A (en) 2024-07-26
PT3265087T (pt) 2020-10-15
CN107427502A (zh) 2017-12-01
KR20250136946A (ko) 2025-09-16
US20190290625A1 (en) 2019-09-26
JP6891385B2 (ja) 2021-06-18
JP2021073258A (ja) 2021-05-13
CN107427502B (zh) 2021-06-04
AU2025210905A1 (en) 2025-08-21
JP2023052486A (ja) 2023-04-11
US12318375B2 (en) 2025-06-03
ES2824552T3 (es) 2021-05-12
JP2024074963A (ja) 2024-05-31
HK1248552A1 (zh) 2018-10-19
IL254142A0 (en) 2017-10-31
AU2021202956B2 (en) 2023-06-29
AU2021202956A1 (en) 2021-06-03
RU2017134443A3 (enExample) 2019-09-05
CA3213864A1 (en) 2016-09-09
KR20170122777A (ko) 2017-11-06
US20190290626A1 (en) 2019-09-26
JP2018507243A (ja) 2018-03-15
US20250205213A1 (en) 2025-06-26

Similar Documents

Publication Publication Date Title
KR102860817B1 (ko) 트라디피턴트에 의한 치료 방법
AU2017315781B2 (en) Use of pridopidine for treating dystonias
KR20090034810A (ko) 멜라토닌 효능제 치료
KR20120050473A (ko) 탈수초성 질환 및 다른 신경계 질환을 앓는 환자에서 신경-인지 및/또는 신경-정신 손상을 개선하기 위한 4-아미노피리딘의 용도
KR102311915B1 (ko) 만성 신장병의 진행 억제 또는 개선제
JP2017527627A (ja) 喫煙者における非小細胞肺癌の治療のための、カルボプラチンおよびパクリタキセルと併用したベリパリブ
TW202327579A (zh) Ｔｅａｄ抑制劑的給藥方案
RU2810253C2 (ru) Способ лечения с применением традипитанта
HK1248552B (en) Method of treatment with tradipitant
JP2000515865A (ja) 過剰攻撃を処置する方法
HK40110657A (zh) 用於治疗癌症的cdk4抑制剂

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

A18 Application divided or continuation or continuation in part accepted

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A18-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)